{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:41:26Z","timestamp":1790836886470,"version":"4.1.0"},"reference-count":69,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2009,2,1]],"date-time":"2009-02-01T00:00:00Z","timestamp":1233446400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,2,1]],"date-time":"2009-02-01T00:00:00Z","timestamp":1233446400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Endocrinology & Metabolism"],"published-print":{"date-parts":[[2009,2]]},"DOI":"10.1016\/j.beem.2008.10.009","type":"journal-article","created":{"date-parts":[[2009,3,12]],"date-time":"2009-03-12T04:23:52Z","timestamp":1236831832000},"page":"65-77","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"title":["The role of the endocannabinoid system in liver diseases"],"prefix":"10.1016","volume":"23","author":[{"given":"Paolo","family":"Caraceni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Domenicali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferdinando","family":"Giannone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Bernardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.beem.2008.10.009_bib1","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1124\/pr.58.3.2","article-title":"The endocannabinoid system as an emerging target of pharmacotherapy","volume":"58","author":"Pacher","year":"2006","journal-title":"Pharmacological Reviews"},{"key":"10.1016\/j.beem.2008.10.009_bib2","doi-asserted-by":"crossref","first-page":"G9","DOI":"10.1152\/ajpgi.00467.2007","article-title":"Endocannabinoids and liver disease. Endocannabinoids and their receptors in the liver","volume":"294","author":"Mallat","year":"2008","journal-title":"American Journal of Physiology. Gastrointestinal and Liver Physiology"},{"key":"10.1016\/j.beem.2008.10.009_bib3","doi-asserted-by":"crossref","first-page":"G1101","DOI":"10.1152\/ajpgi.00057.2008","article-title":"Endocannabinoids and liver disease. Endocannabinoid involvement in obesity and hepatic steatosis","volume":"294","author":"Kunos","year":"2008","journal-title":"American Journal of Physiology. Gastrointestinal and Liver Physiology"},{"key":"10.1016\/j.beem.2008.10.009_bib4","doi-asserted-by":"crossref","first-page":"G357","DOI":"10.1152\/ajpgi.00456.2007","article-title":"Endocannabinoids and liver disease. Endocannabinoids in the pathogenesis and treatment of liver fibrosis","volume":"294","author":"Siegmund","year":"2008","journal-title":"American Journal of Physiology. Gastrointestinal and Liver Physiology"},{"key":"10.1016\/j.beem.2008.10.009_bib5","doi-asserted-by":"crossref","first-page":"G850","DOI":"10.1152\/ajpgi.00523.2007","article-title":"Endocannabinoids and liver disease. Endocannabinoid effects on immune cells: implications for inflammatory liver diseases","volume":"294","author":"Pacher","year":"2008","journal-title":"American Journal of Physiology. Gastrointestinal and Liver Physiology"},{"issue":"Suppl. 1","key":"10.1016\/j.beem.2008.10.009_bib6","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1365-2826.2008.01679.x","article-title":"The endocannabinoid system and liver diseases","volume":"20","author":"Caraceni","year":"2008","journal-title":"Journal of Neuroendocrinology"},{"key":"10.1016\/j.beem.2008.10.009_bib7","series-title":"Disease of the liver and biliary system","first-page":"470","article-title":"Nutritional and metabolic liver disease","author":"Sherlock","year":"1989"},{"key":"10.1016\/j.beem.2008.10.009_bib8","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/hep.20734","article-title":"Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study","volume":"42","author":"Bedogni","year":"2005","journal-title":"Hepatology (Baltimore, Md.)"},{"key":"10.1016\/j.beem.2008.10.009_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cld.2007.02.009","article-title":"Epidemiology and natural history of NAFLD and NASH","volume":"11","author":"Ong","year":"2007","journal-title":"Clinics in Liver Disease"},{"key":"10.1016\/j.beem.2008.10.009_bib10","doi-asserted-by":"crossref","unstructured":"Sampath H, Miyazaki M, Dobrzyn A, et\u00a0al. Stearoyl CoA-desaturase-1 mediates the pro-lipogenic effect of dietary saturated fat. The Journal of Biological Chemistry207(282): 2483\u20132493.","DOI":"10.1074\/jbc.M610158200"},{"key":"10.1016\/j.beem.2008.10.009_bib11","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.cell.2004.11.043","article-title":"Hyperlipidemic effects of dietary saturated fats mediated through PGC-1betacoactivation of SREBP","volume":"120","author":"Lin","year":"2005","journal-title":"Cell"},{"key":"10.1016\/j.beem.2008.10.009_bib12","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1172\/JCI200523057","article-title":"Endocannabinoid activation at hepatic CB(1) receptors stimulates fatty acid synthesis and contributes to diet-induced obesity","volume":"115","author":"Osei-Hyiaman","year":"2005","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1016\/j.beem.2008.10.009_bib13","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.1172\/JCI34827","volume":"118","author":"Osei-Hyiaman","year":"2008","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1016\/j.beem.2008.10.009_bib14","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1002\/hep.21641","article-title":"Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa\/fa rats","volume":"46","author":"Gary-Bobo","year":"2007","journal-title":"Hepatology (Baltimore, Md.)"},{"key":"10.1016\/j.beem.2008.10.009_bib15","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/j.1478-3231.2006.01401.x","article-title":"Endocannabinoid receptor CB2 in nonalcoholic fatty liver disease","volume":"27","author":"Mendez-Sanchez","year":"2006","journal-title":"Liver International"},{"key":"10.1016\/j.beem.2008.10.009_bib16","first-page":"308A","article-title":"CB2 receptor antagonism reduces diet-induced obesity, insulin-resistance and hepatic steatosis","volume":"46","author":"Deveaux","year":"2007","journal-title":"Hepatology (Baltimore, Md.)"},{"key":"10.1016\/j.beem.2008.10.009_bib17","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1097\/MOG.0b013e3282fbceca","article-title":"Alcohol and the liver","volume":"24","author":"Reuben","year":"2008","journal-title":"Current Opinion in Gastroenterology"},{"key":"10.1016\/j.beem.2008.10.009_bib18","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.cmet.2007.12.007","article-title":"Paracrine activation of hepatic CB1 receptors by stellate cell-derived endocannabinoids mediates alcoholic fatty liver","volume":"7","author":"Jeong","year":"2008","journal-title":"Cell Metabolism"},{"key":"10.1016\/j.beem.2008.10.009_bib19","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1111\/j.1572-0241.2005.40898.x","article-title":"Hepatitis C virus-induced hepatocellular steatosis","volume":"100","author":"Castera","year":"2005","journal-title":"The American Journal of Gastroenterology"},{"key":"10.1016\/j.beem.2008.10.009_bib20","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1053\/jhep.2001.24432","article-title":"Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity","volume":"33","author":"Adinolfi","year":"2001","journal-title":"Hepatology (Baltimore, Md.)"},{"key":"10.1016\/j.beem.2008.10.009_bib21","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1136\/gut.2005.069757","article-title":"Steatosis in chronic hepatitis C: why does it really matter?","volume":"55","author":"Asselah","year":"2006","journal-title":"Gut"},{"key":"10.1016\/j.beem.2008.10.009_bib22","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/j.1365-2893.2004.00528.x","article-title":"Different mechanisms of steatosis in hepatitis C virus genotypes 1 and 3 infections","volume":"11","author":"H\u00e9zode","year":"2004","journal-title":"Journal of Viral Hepatitis"},{"key":"10.1016\/j.beem.2008.10.009_bib23","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1053\/j.gastro.2006.03.014","article-title":"Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data","volume":"130","author":"Leandro","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.beem.2008.10.009_bib24","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1002\/hep.21239","article-title":"Impact of obesity on treatment of chronic hepatitis C","volume":"43","author":"Charlton","year":"2006","journal-title":"Hepatology (Baltimore, Md.)"},{"key":"10.1016\/j.beem.2008.10.009_bib25","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1053\/j.gastro.2007.11.039","article-title":"Daily cannabis use: a novel risk factor of steatosis severity in patients with chronic hepatitis C","volume":"134","author":"H\u00e9zode","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.beem.2008.10.009_bib26","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.cld.2006.08.017","article-title":"Hepatic fibrosis, stellate cells, and portal hypertension","volume":"10","author":"Rockey","year":"2006","journal-title":"Clinics in Liver Disease"},{"key":"10.1016\/j.beem.2008.10.009_bib27","doi-asserted-by":"crossref","first-page":"G357","DOI":"10.1152\/ajpgi.00456.2007","article-title":"Endocannabinoids in the pathogenesis and treatment of liver fibrosis","volume":"294","author":"Siegmund","year":"2008","journal-title":"American Journal of Physiology. Gastrointestinal and Liver Physiology"},{"key":"10.1016\/j.beem.2008.10.009_bib28","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1002\/hep.20733","article-title":"Daily cannabis smoking as a risk factor for fibrosis progression in chronic hepatitis C","volume":"42","author":"Hezode","year":"2005","journal-title":"Hepatology (Baltimore, Md.)"},{"key":"10.1016\/j.beem.2008.10.009_bib29","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nm1421","article-title":"CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis","volume":"12","author":"Teixeira-Clerc","year":"2006","journal-title":"Nature Medicine"},{"key":"10.1016\/j.beem.2008.10.009_bib30","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1053\/j.gastro.2004.12.050","article-title":"Antifibrogenic role of the cannabinoid receptor CB2 in the liver","volume":"128","author":"Julien","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.beem.2008.10.009_bib31","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1002\/hep.20667","article-title":"Anandamide induces necrosis in primary hepatic stellate cells","volume":"41","author":"Siegmund","year":"2005","journal-title":"Hepatology (Baltimore, Md.)"},{"key":"10.1016\/j.beem.2008.10.009_bib32","doi-asserted-by":"crossref","first-page":"2798","DOI":"10.1096\/fj.06-7717com","article-title":"The endocannabinoid 2-arachidonyl glycerol induces death of hepatic stellate cells via mitochondrial oxygen species","volume":"21","author":"Siegmund","year":"2007","journal-title":"The FASEB Journal"},{"key":"10.1016\/j.beem.2008.10.009_bib33","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1124\/jpet.107.131896","article-title":"Regression of fibrosis after chronic stimulation of cannabinoid CB2 receptor in cirrhotic rats","volume":"324","author":"Munoz-Luque","year":"2008","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"issue":"Suppl. 2","key":"10.1016\/j.beem.2008.10.009_bib34","doi-asserted-by":"crossref","first-page":"S38","DOI":"10.1016\/S0168-8278(08)60090-2","article-title":"Effect of cannabinoid CB1-receptor antagonism on ascitic decompensation of rats with preascitic cirrhosis","volume":"48","author":"Domenicali","year":"2008","journal-title":"Journal of Hepatology"},{"issue":"Suppl. 1","key":"10.1016\/j.beem.2008.10.009_bib35","doi-asserted-by":"crossref","first-page":"S68","DOI":"10.1016\/j.jhep.2008.01.021","article-title":"The management of portal hypertension: rational basis, available treatments and future options","volume":"48","author":"Bosch","year":"2008","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.beem.2008.10.009_bib36","doi-asserted-by":"crossref","first-page":"G328","DOI":"10.1152\/ajpgi.00367.2005","article-title":"Roles of anandamide in the hepatic microcirculation in cirrhotic rats","volume":"290","author":"Yang","year":"2005","journal-title":"American Journal of Physiology. Gastrointestinal and Liver Physiology"},{"key":"10.1016\/j.beem.2008.10.009_bib37","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1042\/CS20060260","article-title":"Effect of chronic CB1 receptor antagonism on livers of rats with biliary cirrhosis","volume":"112","author":"Yang","year":"2007","journal-title":"Clinical Science"},{"key":"10.1016\/j.beem.2008.10.009_bib38","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1172\/JCI102813","article-title":"The cardiac output at rest in Laennec's cirrhosis","volume":"32","author":"Kowalsky","year":"1953","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1016\/j.beem.2008.10.009_bib39","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1002\/hep.1840080532","article-title":"Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis","volume":"8","author":"Schrier","year":"1988","journal-title":"Hepatology (Baltimore, Md.)"},{"key":"10.1016\/j.beem.2008.10.009_bib40","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1053\/jhep.2002.31432","article-title":"The paradox of nitric oxide in cirrhosis and portal hypertension: too much, not enough","volume":"35","author":"Wiest","year":"2002","journal-title":"Hepatology (Baltimore, Md.)"},{"key":"10.1016\/j.beem.2008.10.009_bib41","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1124\/jpet.103.057315","article-title":"Role of the heme oxygenases in abnormalities of the mesenteric circulation in cirrhotic rats","volume":"308","author":"Sacerdoti","year":"2004","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.beem.2008.10.009_bib42","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1002\/hep.1840180322","article-title":"Role of prostacyclin in hemodynamic alterations in conscious rats with extrahepatic or intrahepatic portal hypertension","volume":"18","author":"Oberti","year":"1993","journal-title":"Hepatology (Baltimore, Md.)"},{"key":"10.1016\/j.beem.2008.10.009_bib43","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/89953","article-title":"Endocannabinoids acting at vascular CB1 receptors mediate the vasodilated state in advanced liver cirrhosis","volume":"7","author":"Batkai","year":"2001","journal-title":"Nature Medicine"},{"key":"10.1016\/j.beem.2008.10.009_bib44","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1053\/gast.2002.30305","article-title":"A new system involved in the homeostasis of arterial pressure in experimental cirrhosis in the rat","volume":"122","author":"Ros","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.beem.2008.10.009_bib45","doi-asserted-by":"crossref","first-page":"53","DOI":"10.2174\/1568010023344878","article-title":"Endocannabinoid degradation, endotoxic shock and inflammation","volume":"1","author":"Maccarrone","year":"2002","journal-title":"Current Drug Targets. Inflammation and Allergy"},{"key":"10.1016\/j.beem.2008.10.009_bib46","doi-asserted-by":"crossref","first-page":"G14","DOI":"10.1152\/ajpgi.2001.280.1.G14","article-title":"Systemic and portal hemodynamic effects of anandamide","volume":"280","author":"Garcia","year":"2001","journal-title":"American Journal of Physiology. Gastrointestinal and Liver Physiology"},{"key":"10.1016\/j.beem.2008.10.009_bib47","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1016\/S0024-3205(02)02086-6","article-title":"Cannabinoid modulation of sensory neurotransmission via cannabinoid and vanilloid receptors: roles in regulation of cardiovascular function","volume":"71","author":"Ralevic","year":"2002","journal-title":"Life Sciences"},{"key":"10.1016\/j.beem.2008.10.009_bib48","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1136\/gut.2004.051599","article-title":"Increased anandamide induced relaxation in mesenteric arteries of cirrhotic rats: role of cannabinoid and vanilloid receptors","volume":"54","author":"Domenicali","year":"2005","journal-title":"Gut"},{"key":"10.1016\/j.beem.2008.10.009_bib49","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1038\/sj.bjp.0706928","article-title":"Anandamide mediates hyperdynamic circulation in cirrhotic rats via CB(1) and VR(1) receptors","volume":"149","author":"Moezi","year":"2006","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.beem.2008.10.009_bib50","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/j.1478-3231.2004.0945.x","article-title":"Circulating endogenous cannabinoid anandamide and portal, systemic and renal hemodynamics in cirrhosis","volume":"24","author":"Fern\u00e1ndez-Rodriguez","year":"2004","journal-title":"Liver International"},{"key":"10.1016\/j.beem.2008.10.009_bib51","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/j.lfs.2005.05.012","article-title":"The search for the palmitoylethanolamide receptor","volume":"77","author":"Lo Verme","year":"2005","journal-title":"Life Sciences"},{"key":"10.1016\/j.beem.2008.10.009_bib52","first-page":"21","article-title":"Palmitoylethanolamide, endocannabinoids and related cannabimimetic compounds in protection against tissue inflammation and pain: potential use in companion animals","volume":"173","author":"Re","year":"2007","journal-title":"Veterinary Journal (London, England : 1997)"},{"key":"10.1016\/j.beem.2008.10.009_bib53","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/ncpgasthep0498","article-title":"Therapy insight: cirrhotic cardiomyopathy","volume":"3","author":"Gaskari","year":"2006","journal-title":"Nature Clinical Practice. Gastroenterology & Hepatology"},{"key":"10.1016\/j.beem.2008.10.009_bib54","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/j.jhep.2005.10.034","article-title":"Cardiac electrophysiological abnormalities in patients with cirrhosis","volume":"44","author":"Zambruni","year":"2006","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.beem.2008.10.009_bib55","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/sj.bjp.0706331","article-title":"Role of endocannabinoids in the pathogenesis of cirrhotic cardiomyopathy in bile duct-ligated rats","volume":"146","author":"Gaskari","year":"2005","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.beem.2008.10.009_bib56","doi-asserted-by":"crossref","first-page":"H1689","DOI":"10.1152\/ajpheart.00538.2007","article-title":"Endocannabinoids acting at CB1 receptors mediate the cardiac contractile dysfunction in vivo in cirrhotic rats","volume":"293","author":"Batkai","year":"2007","journal-title":"American Journal of Physiology. Heart and Circulatory Physiology"},{"key":"10.1016\/j.beem.2008.10.009_bib57","first-page":"251","article-title":"Liver ischemia for hepatic resection: where is the limit?","volume":"111","author":"Huguet","year":"1992","journal-title":"Surgery"},{"key":"10.1016\/j.beem.2008.10.009_bib58","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1055\/s-2001-12933","article-title":"Fatty liver in liver transplantation and surgery","volume":"21","author":"Selzner","year":"2001","journal-title":"Seminars in Liver Disease"},{"key":"10.1016\/j.beem.2008.10.009_bib59","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1002\/hep.1840200410","article-title":"Selecting the donor liver: risk factors for poor function after orthotopic liver transplantation","volume":"20","author":"Strasberg","year":"1994","journal-title":"Hepatology (Baltimore, Md.)"},{"key":"10.1016\/j.beem.2008.10.009_bib60","doi-asserted-by":"crossref","first-page":"G1083","DOI":"10.1152\/ajpgi.00568.2005","article-title":"Mechanisms of Liver Injury. II. Mechanisms of neutrophil-induced liver cell injury during hepatic ischemia-reperfusion and other acute inflammatory conditions","volume":"290","author":"Jaeschke","year":"2006","journal-title":"American Journal of Physiology. Gastrointestinal and Liver Physiology"},{"key":"10.1016\/j.beem.2008.10.009_bib61","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1080\/08941930590905189","article-title":"2-arachidonylglycerol increases in ischemia-reperfusion injury of rat liver","volume":"18","author":"Kurabayashi","year":"2005","journal-title":"Journal of Investigative Surgery"},{"key":"10.1016\/j.beem.2008.10.009_bib62","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1096\/fj.06-7451com","article-title":"Cannabinoid-2 receptor mediates protection against hepatic ischemia-reperfusion injury","volume":"21","author":"Batkai","year":"2007","journal-title":"The FASEB Journal"},{"key":"10.1016\/j.beem.2008.10.009_bib63","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1189\/jlb.0307180","article-title":"Cannabinoid-2 receptor agonist HU-308 protects against hepatic ischemia-reperfusion injury by attenuating oxidative stress, inflammatory response, and apoptosis","volume":"82","author":"Rajesh","year":"2007","journal-title":"Journal of Leukocyte Biology"},{"key":"10.1016\/j.beem.2008.10.009_bib64","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/sj.bjp.0707582","article-title":"Endocannabinoids and cannabinoid receptors in ischemia-reperfusion injury and preconditioning","volume":"153","author":"Pacher","year":"2008","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.beem.2008.10.009_bib65","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1097\/00024382-199610001-00004","article-title":"The gut in critical illness: evidence from human studies","volume":"6","author":"Marshall","year":"1996","journal-title":"Shock"},{"key":"10.1016\/j.beem.2008.10.009_bib66","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1097\/00024382-200116040-00014","article-title":"Lung and liver injury following hepatic ischemia\/reperfusion in the rat is increased by exogenous lipopolysaccaride which also increases hepatic TNF production in vivo and in vitro","volume":"16","author":"Colletti","year":"2001","journal-title":"Shock (Augusta, Ga.)"},{"key":"10.1016\/j.beem.2008.10.009_bib67","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/j.1432-2277.2003.tb00293.x","article-title":"Regulation of pro-inflammatory and anti-inflammatory cytokine responses by Kupffer cells in endotoxin-enhanced reperfusion injury after total hepatic ischemia","volume":"16","author":"Kojima","year":"2003","journal-title":"Transplant International"},{"key":"10.1016\/j.beem.2008.10.009_bib68","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1189\/jlb.0504309","article-title":"Critical role of CXC chemokines in endotoxemic liver injury in mice","volume":"76","author":"Jaeschke","year":"2004","journal-title":"Journal of Leukocyte Biology"},{"key":"10.1016\/j.beem.2008.10.009_bib69","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1038\/nrd2553","article-title":"targeting the endocannabinoid system: to enhance or reduce?","volume":"7","author":"Di Marzo","year":"2008","journal-title":"Nature Reviews. Drug Discovery"}],"container-title":["Best Practice & Research Clinical Endocrinology & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X08001371?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X08001371?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T16:40:50Z","timestamp":1761496850000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521690X08001371"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,2]]},"references-count":69,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,2]]}},"alternative-id":["S1521690X08001371"],"URL":"https:\/\/doi.org\/10.1016\/j.beem.2008.10.009","relation":{},"ISSN":["1521-690X"],"issn-type":[{"value":"1521-690X","type":"print"}],"subject":[],"published":{"date-parts":[[2009,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of the endocannabinoid system in liver diseases","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Endocrinology & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beem.2008.10.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2008 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}